Financials
Financial year 2025
FASYLPHARMA from Aiseau-Presles, company number BE0478056184, closed financial year 2025 with a result of € 15,509 after tax. For that financial year FASYLPHARMA recorded a gross margin of € 39,372 and equity of € 234,342. Compared with financial year 2024, the result moved from € 26,802 to € 15,509. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on February 23, 2026.
€ 234,342
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 15,509
▼ 42% vs 2024
Profit after tax over the fiscal year.
€ 85,763
▼ 17% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 228,142.
People and assets in 2025
€ 2,902
▼ 76% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2,576
▼ 91% vs 2024
Loans from banks and other lenders, long and short.
€ 7,792
▲ 8% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,576
▲ € 5,092 vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 69,007 | € 49,088 | € 53,232 | € 39,372 | ▼ 26% |
| Profit after taxes | € 34,599 | € 24,118 | € 26,802 | € 15,509 | ▼ 42% |
| Equity | € 241,750 | € 222,031 | € 218,833 | € 234,342 | ▲ 7% |
| Total debts | € 81,388 | € 89,488 | € 66,043 | € 15,976 | ▼ 76% |
| Cash | € 128,260 | € 107,997 | € 102,826 | € 85,763 | ▼ 17% |
| Land & buildings | € 56,421 | € 52,945 | € 49,469 | € 45,993 | ▼ 7% |
| Retained profit | € 235,550 | € 215,831 | € 212,633 | € 228,142 | ▲ 7% |
| Dividend | € 0 | € 41,645 | € 30,000 | € 0 | ▼ 100% |
| Bank debt | € 74,033 | € 50,209 | € 28,345 | € 2,576 | ▼ 91% |
| Balance sheet total | € 323,138 | € 311,518 | € 284,875 | € 250,318 | ▼ 12% |
Key figures of FASYLPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to FASYLPHARMA?
What happened at FASYLPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 15,509 (▼ 42% vs 2024). filed late Source: NBB ↗
- Fabrice HENROTTIN became a director. NBB
- Sylvie BIANCO became a director. NBB
- New establishment in Aiseau-Presles. KBO
- Start of the company according to the CBE. KBO
In short
From € 34,599 profit in 2022 to € 15,509 profit in 2025.
Paid € 37,954 in corporate taxes since 2022.
Best year ever: 2022, with € 34,599 profit.
Paid out € 71,645 in dividends to the owners in total.
Management
Behind FASYLPHARMA are Fabrice HENROTTIN and Sylvie BIANCO.
Directors
According to the 2025 annual accounts
Fabrice HENROTTIN
Manager, Director
since 2023
Sylvie BIANCO
Director, Manager
since 2023
Establishments
Establishment units
Physical locations of this company
Rue François Dimanche(RO) 21
6250 Aiseau-Presles
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0478.056.184
- VAT number
- BE 0478.056.184
- Registered office
- Rue François Dimanche(RO) 21, 6250 Aiseau-Presles
- Names & denominations
- FASYLPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 July 2002
- Peppol
- Active · Active since 8 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers